查找临床试验
已按「阵发性睡眠性血红蛋白尿」检索，对应国际通用词 paroxysmal nocturnal hemoglobinuria
共找到 18 项正在招募的试验（在欧美日韩等发达国家设有中心）
数据更新于 00:26，每 5 分钟自动同步A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Brazil、Canada、Italy、Poland、South Korea 等 7 国
年龄 18 Years – 不限
Regeneron Pharmaceuticals
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
United States、Brazil、Colombia、Germany、Italy 等 6 国
年龄 2 Years – 18 Years
Novartis Pharmaceuticals
Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic Data
Italy
年龄 28 Days – 65 Years
Istituto Giannina Gaslini
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
Canada、South Korea、United Kingdom
年龄 18 Years – 不限
Regeneron Pharmaceuticals
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
United States、Australia、France、Germany、Italy 等 7 国
年龄 不限 – 不限
Alexion Pharmaceuticals, Inc.
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Brazil、Canada、Colombia、Hungary、India 等 12 国
年龄 18 Years – 不限
Regeneron Pharmaceuticals
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Australia、United Kingdom
年龄 18 Years – 不限
ADARx Pharmaceuticals, Inc.
Home Reported Outcomes in PNH
United States
年龄 18 Years – 99 Years
Novartis Pharmaceuticals
The International PNH Interest Group PNH Registry
United States
年龄 不限 – 不限
International PNH Interest Group
Global PNH Patient Registry
United States
年龄 不限 – 不限
Aplastic Anemia and MDS International Foundation
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
United States
年龄 0 Years – 75 Years
Masonic Cancer Center, University of Minnesota
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
United States
年龄 4 Years – 75 Years
National Heart, Lung, and Blood Institute (NHLBI)